Cancer GeneticsWeb
www.cancer-genetics.org
Navigate
Disclaimer: This site is for educational purposes only; it can not be used in diagnosis or treatment.
  Prostate Cancer

Mutated Genes and Abnormal Protein Expression (40)
Recurrent Chromosome Abnormalities (2)
Overview of the Molecular Biology of Prostate Cancer
Familial Prostate Cancer
del(8p22) in Prostate Cancer
Chromosome Y Abnormalities in Prostate Cancer
Prostate Cancer: Clinical and Epidemiological Resources
  Mutated Genes and Abnormal Protein Expression
GeneLocationTopics
EEF1A1L14 ( PTI1 ) -EEF1A1L14 and Prostate Cancer
HPC1 ( PCS1 ) 1q24-q25 -HPC1 and Familial Prostate Cancer
PRCA11q24-q25 -PRCA1 and Prostate Cancer ?
PCAP ( HPC2 ) 1q42.2-1q43 -PCAP and Familial Prostate Cancer
SRD5A22p23 -SRD5A2 and Prostate Cancer
BIN1 ( AMPHL , SH3P9 ) 2q14 -BIN1 and Prostate Cancer
CTNNB1 ( CTNNB ) 3p22-p21.3 -CTNNB1 and Prostate Cancer
TGM4 ( pTGase ) 3p22-p21.33 -TGM4 Expression and Prostate Cancer
ACPP3q21-q23 -PAP (ACPP) Expression and Prostate Cancer Prognosis
FGF2 ( FGFB , BFGF ) 4q25-q27 -FGF2 Over-Expression in Prostate Cancer
FGF1 ( FGFA ) 5q31 -FGF1 Over-Expression in Prostate Cancer
SPARC ( ON , OSN , BM-40 ) 5q31.3-q32 -SPARC Expression and Prostate Cancer
VEGF ( VEGFA ) 6p12 -VEGF and Prostate Cancer
CDKN1A ( P21 , WAF1 , CIP1 ) 6p21.2 -CDKN1A Expression in Prostate Cancer
IL6 ( IFNB2 ) 7p21 -IL6 and Prostate Cancer
CYP3A47q22.1 -CYP3A4 and Prostate Cancer
CAV1 ( Caveolin-1 ) 7q31.1 -CAV1 and Prostate Cancer
PDGFRL ( PRLTS ) 8p22-p21.3 (?) -PDGFRL and Prostate Cancer
PSCA8q24.2 -PSCA and Prostate Cancer
MSMB ( PSP94 , PSP57 ) 10q11.2 -MSMB Expression and Prostate Cancer
PTEN ( MMAC1 , MHAM , BZS ) 10q23.3 -PTEN and Prostate Cancer
FGF8 ( AIGF ) 10q24 -FGF8 Over-Expression in Prostate Cancer
CYP1710q24.3 -CYP17 and Prostate Cancer
MXI110q25 -MXI1 and Prostate Cancer
MKI67 ( Ki-67 ) 10q25-qter -Ki-67 Expression in Prostate Cancer
KAI1 ( CD82 , R2 , ST6 ) 11p11.2 -KAI1 and Prostate Cancer
POV1 ( PB39 ) 11p11.2-11p11.1 -POV1 and Prostate Cancer
CDKN1B ( KIP1 , P27 ) 12p13 -CDKN1B and Prostate Cancer
IGF112q22-q24.1 -IGF1 Expression in Prostate Cancer
TP53 ( p53 , P53 ) 17p13.1 -TP53 and Prostate Cancer
ERBB2 ( HER2 , NEU ) 17q11.2-q12 -ERBB2 and Prostate Cancer
PI5 ( maspin ) 18q21.3 -Maspin and Prostate Cancer
KLK3 ( PSA , APS ) 19q13 -Prostate Specific Antigen and Prostate Cancer
-Use of Percent Free PSA in Prostate Cancer Staging
KLK2 ( hK2 ) 19q13 -KLK2 Expression and Prostate Cancer Prognosis
BGP1 ( CD66A , C-CAM1 , CEACAM1 ) 19q13.2 -CD66a and Prostate Cancer
ETS221q22.3 -ETS2 and Prostate Cancer
TMPRSS2 ( PRSS10 ) 21q22.3 -TMPRSS2 and Prostate Cancer
AR ( DHTR ) Xq11.2-q12 -AR and Prostate Cancer
HPCXXq27-q28 -HPCX and Hereditary Prostate Cancer
SRYYp11.3 -SRY Deletion in Prostate Cancer

 

  Recurrent Chromosome Abnormalities

del(8p22) in Prostate Cancer
Chromosome Y Abnormalities in Prostate Cancer

Related links:
Recurrent Chromosome Abnormalities - Prostate (Cancer Genome Anatomy Project)
  Overview of the Molecular Biology of Prostate Cancer

Prostate cancer is the most common malignancy found in men, incidence is highest among American Blacks and lowest in East Asian populations. Prostate specific Antigen (PSA) is an important marker in the diagnosis and monitoring of prostate cancer, and the percentage free PSA has been shown to have prognostic significance in some studies.

Androgens, which exert their effects via the androgen receptor (AR), are essential for the normal prostate. They are also required by prostate cancer cells. Therefore, androgen ablation and antiandrogen therapy are important in the treatment of the disease, though most patients go on to develop androgen-independent prostate cancer. Androgen receptor mutations are observed in late stage prostate cancer.

Caveolin-1 is overexpressed in about a quarter of human prostate cancers (Yang, 1999) . Caveolin expression is thought to induce androgen sensitivity in androgen-insensitive prostate cancer cells.

Mutations in a diverse range of other genes have been implicated in prostate cancer including PTEN, KAI1, SRD5A2, and IL6. Most of these relate to disease progression.

Hereditary prostate cancer accounts for about 9% of cases. A prostate cancer susceptibility locus (HPC1) on chromosome 1q24-25 was identified by Smith (1996). However, subsequent studies suggest that mutations in HPC1 are uncommon and are restricted to people with early onset disease. A second gene (HPC2 on chromosome 1q42.2-q43 was proposed by Berthon (1998), though again subsequent linkage studies indicate this gene could only account for a small proportion of cases. Other specific gene(s) associated with hereditary prostate cancer have yet to be identified.

  • Jenster G. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol. 1999; 26(4):407-21. [Review]    Related articles (PubMed)

  • Daliani D, Papandreou CN. Markers of androgen-independent progression of prostatic carcinoma. Semin Oncol. 1999; 26(4):399-406. [Review]    Related articles (PubMed)

  • Bangma CH, et al. Metastasis-related genes in prostate cancer. Semin Oncol. 1999; 26(4):422-7. [Review]    Related articles (PubMed)

  • Brothman AR, et al. Chromosomal clues to the development of prostate tumors. Prostate 1999 Mar 1;38(4):303-12    Related articles (PubMed)

  • Medline Search: prostate cancer AND genetics (PubMed)   Limit search to: [Last Year]  Limit search to: [Last 2 Years]   Limit search to: [Reviews]

    Related Resources
  • Familial Prostate Cancer
  • Prostate Cancer - Microbiology
  •  

  •   Familial Prostate Cancer

    Hereditary prostate cancer accounts for about 9% of cases. A prostate cancer susceptibility locus (HPC1) on chromosome 1q24-25 was idenified by Smith (1996). However, McIndoe (1997) found no evidence of HPC1 mutation in 49 high-risk families. Also in a study of "small" families [3-5 affected members], Dunsmuir (1998) found less than 8% of cases had allelic loss in HPC1. Other studies suggest that mutations in HPC1 are uncommon and are restricted to people with early onset disease.

    Other candidate genes have been proposed. HPCX at chromosome Xq27-28 was identified by a large international linkage study of 360 families (Xu, 1998). Another locus - HPC2 (PCAP) on chromosome 1q42.2-q43 was proposed by Berthon (1998), though a subsequent linkage study (Gibbs, 1999) indicated this gene could only account for a small proportion of cases.

    Other specific gene(s) associated with familial prostate cancer have yet to be identified.

  • Gibbs M, et al. Analysis of Chromosome 1q42.2-43 in 152 Families with High Risk of Prostate Cancer. Am J Hum Genet 1999; 64(4):1087-1095    Related articles (PubMed)

  • Berthon P, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998; 62(6):1416-24    Related articles (PubMed)

  • Ekman P Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. [Review] Eur Urol 1999;35(5-6):362-9    Related articles (PubMed)

  • Dunsmuir WD, et al. Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. Br J Cancer 1998;78(11):1430-3    Related articles (PubMed)

  • Gronberg H, et al. In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. Am J Hum Genet. 1999;65(1):134-40    Related articles (PubMed)

  • McIndoe RA, et al. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet 1997; 61(2):347-53    Related articles (PubMed)

  • Carter BS, et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89(8):3367-71    Related articles (PubMed)

  • Medline Search: familial prostate cancer (PubMed)   Limit search to: [Last Year]  Limit search to: [Last 2 Years]   Limit search to: [Reviews]

    Related Resources
  • HPC1
  • HPC2 (PCAP)
  •  

  •   del(8p22) in Prostate Cancer

  • Arbieva ZH, et al. High-Resolution Physical Map and Transcript Identification of a Prostate Cancer Deletion Interval on 8p22. Genome Res 2000;10(2):244-257    Related articles (PubMed)

  • Bova GS, et al. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 1996; 35(1):46-54.    Related articles (PubMed)

  • Medline Search: prostate cancer AND chromosome 8 (PubMed)   Limit search to: [Last Year]  Limit search to: [Last 2 Years]   Limit search to: [Reviews]

    Prostate Cancer Genetics
    Prostate Cancer : Clinical and Epidemiological Information
    Chromosme 8

     

  •   Chromosome Y Abnormalities in Prostate Cancer

  • Perinchery G, et al. Deletion of Y-chromosome specific genes in human prostate cancer. J Urol 2000;163(4):1339-42    Related articles (PubMed)

  • Lau YF, Zhang J Expression analysis of thirty one Y chromosome genes in human prostate cancer. Mol Carcinog 2000;27(4):308-21    Related articles (PubMed)

  • Medline Search: prostate cancer AND chromosome Y (PubMed)   Limit search to: [Last Year]  Limit search to: [Last 2 Years]   Limit search to: [Reviews]

    Prostate Cancer Genetics
    Prostate Cancer : Clinical and Epidemiological Information
    Chromosme Y

     

  •  [Home]       © Copyright 1999-